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Prominent Production of IL-20 by CD68þ /CD11cþ
Myeloid-Derived Cells in Psoriasis: Gene Regulation
and Cellular Effects
Frank Wang1,2, Edmund Lee1,2, Michelle A. Lowes1, Asifa S. Haider1, Judilyn Fuentes-Duculan1,
Maria Veronica Abello1, Francesca Chamian1, Irma Cardinale1 and James G. Krueger1
We assessed expression of IL-20 and its receptors in psoriasis, given the recent implication of IL-20 in epidermal
hyperplasia. Psoriatic lesional (LS) skin consistently expressed more IL-20 mRNA than nonlesional (NL) skin.
Immunoreactivity to IL-20 protein was greater in LS tissue and mainly localized to infiltrating CD68þ /CD11cþ
(myeloid-derived) dermal leukocytes. Because this contrasted with earlier reports of a keratinocyte source, we
assessed IL-20 mRNA expression in a variety of cells in vitro, and confirmed a myeloid-derived cellular source
(monocytes). Plastic adhesion, activation of b2 integrins, and incubation with tumor necrosis factor-a stimulated
expression in these cells. IL-20 receptor (IL-20R)a and IL-20Rb mRNA was decreased in LS versus NL skin, which
also contrasted with earlier findings. To investigate the relationship between IL-20 and disease activity, we
examined psoriasis patients treated with the CD2-targeted agent alefacept. In therapeutic responders, lesional
IL-20 mRNA decreased to NL levels, suggesting that CD2þ leukocytes may proximally regulate IL-20. Finally, to
assess IL-20 function, we used microarrays to screen IL-20-treated keratinocytes, which demonstrated
upregulation of disease-related and IFN-g-induced genes. Hence, IL-20 may influence inflammation through
IFN-like effects. Together, these data indicate that IL-20 may be an important effector cytokine in psoriasis, and
that its inhibition may represent a potential therapeutic target.
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INTRODUCTION
IL-20 is a recently discovered cytokine implicated in pso-
riasis. IL-20 belongs to the IL-10 cytokine family (Blumberg
et al., 2001), which also includes IL-19 (Gallagher et al., 2000),
IL-22 (Dumoutier et al., 2000), IL-24 (MDA-7) (Jiang et al.,
1996), and IL-26 (AK155) (Knappe et al., 2000). In contrast to
IL-10, which suppresses psoriasis and other T-cell-mediated
diseases (Moore et al., 2001), IL-20 exhibits proinflammatory
properties. For instance, keratinocytes stimulated with
IL-20 (in combination with IL-1) upregulate a variety of
inflammatory genes (Blumberg et al., 2001), including tumor
necrosis factor-a (TNF-a), monocyte chemotactic protein-1
(MCP-1), and myeloid-related protein-14 (MRP-14) (Rich and
Kupper, 2001).
In transgenic mice, overexpression of IL-20 induces
neonatal lethality and skin abnormalities, including a
wrinkled, shiny appearance (Blumberg et al., 2001). Histo-
logically, these mice lack the immune infiltrates found in
human psoriatic skin, but display hyperproliferative skin
features, including a thickened epidermis and elevated
markers of hyperproliferation (e.g. keratin 6). The authors
have suggested that this is consistent with a psoriasis-like
phenotype.
In humans, lesional (LS) psoriatic skin contains elevated
IL-20 mRNA, which diminishes after short-term treatment
with cyclosporine A or calcipotriol (Romer et al., 2003; Wei
et al., 2005). To date, IL-20 protein has been localized to
basal and suprabasal keratinocytes (Wei et al., 2005). Gene
and protein expression for the receptor subunits IL-20
receptor (IL-20R)a and IL-20Rb are also increased in psoriasis
(Blumberg et al., 2001; Romer et al., 2003; Wei et al., 2005).
IL-20 binds two heterodimeric receptors, Type I IL-20R
consisting of IL-20Ra/IL-20Rb and Type II IL-20R consisting of
IL-20Rb/IL-22R (Dumoutier et al., 2001; Parrish-Novak et al.,
2002). Type I IL-20R also binds IL-19 and IL-24, whereas
Type II IL-20R also binds IL-24. All of the subunits are highly
expressed in the epidermis (Blumberg et al., 2001; Dumoutier
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et al., 2001), suggesting that IL-20 affects keratinocyte
function.
Given the potential importance of this cytokine, we
assessed the expression of IL-20 and IL-20R in psoriatic skin
and attempted to identify the cell types and regulatory factors
responsible for IL-20 synthesis. We found IL-20 mRNA, but
not IL-20R mRNA, to be tremendously increased in psoriasis.
Myeloid-derived (CD68þ /CD11cþ ) cells at the dermo-
epidermal junction and within the epidermis appear to be
an important source of IL-20. Synthesis of the cytokine is
regulated by cell adhesion and exposure to TNF-a. In
keratinocytes, exposure to IL-20 upregulates the expression
of inflammatory genes, including IFN-responsive elements.
Lastly, we report that IL-20 expression is highly correlated
with disease activity and suppressed by treatment with
alefacept (LFA-3TIP, anti-CD2, Amevive, Biogen Idec),
implying that IL-20 is a product of leukocyte-driven
inflammation.
RESULTS
IL-20 mRNA is consistently upregulated in psoriasis
We obtained mRNA from matched LS and nonlesional (NL)
psoriatic skin and performed real-time, reverse transcriptase-
PCR (RT-PCR) to quantify IL-20 mRNA. Values were normal-
ized to the housekeeping gene human acidic ribosomal
protein (hARP). In all psoriasis patients (34/34), we found
IL-20 mRNA to be elevated in LS skin compared to NL skin
(Figure 1a). Mean expression in NL skin was 16.1 (arbitrary
scale), whereas expression in LS skin was 726.2 and elevated
45-fold (range 3- to 565-fold, Po0.0001). In comparison,
mean expression of IL-20 in 11 control patients without
psoriasis was 8.62, which was significantly less than LS and
NL skin (Po0.0001 and P¼ 0.039, respectively).
IL-20 receptor mRNA is decreased in psoriasis
We next characterized the expression of IL-20Ra, IL-20Rb, and
IL-22R. We found mRNA for all subunits to be decreased in LS
skin (Figure 1b–d). Using hARP to normalize values, mean
expression in NL versus LS skin, respectively, was 5.8 vs 3.8
for IL-20Ra (P¼ 0.046, n¼13), 5.0 vs 3.4 for IL-20Rb (P¼
0.019, n¼13), and 3.3 vs 2.3 for IL-22R (P¼0.157, n¼7).
Difference in expression was significant for IL-20Ra and IL-
20Rb, but not for IL-22R. In contrast to published data
(Blumberg et al., 2001), we found mRNA for the subunits to be
expressed in unaffected, normal skin (Figure 1b–d). Mean
expression was 4.7 for IL-20Ra (n¼11), 4.5 for IL-20Rb (n¼
11), and 2.5 for IL-22R (n¼8). These values were not signi-
ficantly different from those of LS and NL skin (both P40.05).
Protein expression of IL-20 and IL-20Ra is consistent
with mRNA expression
To confirm the above findings, we stained skin sections for
IL-20 and IL-20Ra. At the time of manuscript preparation, no
commercial antibodies for IL-20Rb or IL-22R were available.
We found that staining for IL-20 and IL-20Ra matched mRNA
expression. For IL-20, we found little staining in normal and
NL skin (Figure 2a and b). In contrast, staining in LS skin
occurred in many cells and with greater intensity (Figure 2c).
Although weak staining of keratinocytes was sometimes
noticed, positive staining appeared greatest in mononuclear
leukocytes in the papillary dermis and along the dermo-
epidermal junction (Figure 2d). In some LS skin biopsies,
strong staining also appeared in leukocytes in the mid-
epidermis and along dermal capillary endothelium (Figure
2c). Immunostaining of IL-20Ra demonstrated two major
findings (Figure 2e and f). Firstly, staining was restricted to
keratinocytes in both NL and LS skin. Secondly, whereas
staining was diffuse and uniform throughout the epidermis of
NL skin, staining was decreased in LS skin and, specifically,
less intense in the lower and middle epidermis, suggesting
that keratinocytes in these areas had decreased expression of
IL-20Ra protein.
IL-20 mRNA is expressed by monocytes in vitro
Having found immunostaining in leukocyte-like cells, we
further investigated the source of IL-20 by examining mRNA
expression in keratinocytes (HaCaT cells) and various cells
isolated from normal blood (Figure 3a). We detected low
expression in unfractionated peripheral blood mononuclear
cells (PBMCs), but almost no expression in lymphocytes
(consisting of natural killer, T, and B cells), unactivated
T cells, T cells activated by CD3 and CD28 ligation,
unactivated HaCaT cells, and HaCaT cells activated by IFN-g.
As PBMCs produced low quantities of IL-20 mRNA, whereas
lymphocytes produced almost none, we fractioned PBMCs to
specifically examine monocytes. Monocytes in suspension
produced substantial amounts of IL-20 mRNA. More drama-
tically, monocytes adherent to polystyrene tissue culture
plastic surface produced the highest quantities and nearly four
times more IL-20 mRNA than nonadherent monocytes.
We then tested whether in vitro monocyte-derived cells
produced IL-20 mRNA. Monocytes were differentiated into
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Figure 1. Gene expression of IL-20 and its receptor subunits in NL
psoriatic skin, LS psoriatic skin, and normal skin. RT-PCR quantification of
(a) IL-20, (b) IL-20Ra, (c) IL-20Rb, and (d) IL-22R, normalized to hARP. A thin
black line connects paired samples from an individual psoriasis patient’s
NL and LS skin. For normal skin, each dot represents one patient. ~ Indicates
the mean for each tissue type, and this symbol obscures individual dots in (a).
Asterisk (*) indicates statistical significance (Po0.05) between NL and LS
psoriatic skin.
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immature dendritic cells (DCs) by incubation with GM-CSF
and IL-4 (Dhodapkar et al., 2002). Mature DCs were then
generated by adding a cocktail of TNF-a, IL-1b, IL-6, and
prostaglandin E2. We found that only monocytes, but not
immature or mature DCs, produced substantial IL-20 mRNA
(Figure 3b). To verify the phenotype of these cells, we also
measured various cellular markers. Consistent with pheno-
type, monocytes expressed CD11c and CD68 mRNA, mature
DCs produced high levels of CD83 and DC-LAMP mRNA,
and immature DCs produced low levels of CD83 mRNA.
Monocytes produce IL-20 in response to b2-integrin activation
or TNF-a
Having found that adherence elicited IL-20 mRNA expres-
sion, we suspected that integrins may stimulate IL-20 pro-
duction. Indeed, monocytes produce inflammatory molecules,
a b c
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Figure 2. Immunohistochemical analysis of IL-20 and IL-20Ra in psoriasis. IL-20 antibody staining of (a) normal skin, (b) NL psoriatic skin, and (c) LS psoriatic
skin (original magnification  10). (d)  40 magnification of the region outlined in (c). IL-20Ra antibody staining of (e) NL and (f) LS psoriatic skin (original
magnification  20). Positive cells appear brown (3-amino-9-ethylcarbazole staining). Bar¼ 100mm.
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Figure 3. Production of IL-20 mRNA by adherent monocytes in vitro, and induction of IL-20 by b2 integrin or TNF-a. (a) IL-20 mRNA was measured in
PBMCs, unfractionated lymphocytes (Lymph) (comprised of T, B, and natural killer cells), monocytes adherent to plastic surface (Ad monos), monocytes in
suspension (Susp monos), unactivated T cells (Unact T cells), T cells activated by CD3 and CD28 ligation (Act T cells), unactivated HaCaT cells (Unact HaCaT),
and HaCaT cells activated by IFN-g (Act HaCaT). (b) Gene expression of IL-20 and cellular/maturational markers was measured in pure monocytes and
monocyte-derived immature DCs (IDCs) and mature DCs (MDCs). Lines demonstrate progression of mRNA expression with maturation. (c) IL-20 mRNA was
analyzed in monocytes activated by integrin ligation. Two different antibody clones against either b1 or b2 integrin were incubated with monocytes in
suspension. (d) IL-20 mRNA was measured in monocytes at baseline (0 hour) and monocytes stimulated with no cytokine, IFN-g, or TNF-a for 6, 24, or 48 hours.
All gene results were normalized to hARP expression.
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such as TNF-a, following integrin ligation to surfaces or
extracellular matrix. This process is known as ‘‘outside-in’’
integrin-mediated signaling (de Fougerolles and Koteliansky,
2002). We found that nonadherent monocytes incubated
with a b2 integrin (CD18) antibody upregulated IL-20 mRNA
more than two-fold versus control (mouse IgG) (Figure 3c). In
contrast, a different b2 integrin antibody (from a different
clone) and two separate b1 integrin antibodies did not
upregulate IL-20.
As cytokines are produced in response to integrin ligation
and may themselves be stimulatory, we considered that IL-20
may be induced by specific cytokines. To investigate this, we
incubated monocytes with IFN-g or TNF-a. Monocytes incu-
bated with TNF-a for 24 hours upregulated IL-20 mRNA
maximally (45-fold vs time-matched control) (Figure 3d).
Monocytes incubated with TNF-a for 6 or 48 hours also
upregulated IL-20 mRNA, but to a lesser degree. Monocytes
incubated with IFN-g for 6, 24, or 48 hours downregulated
IL-20 production by a small degree compared to time-
matched controls.
IL-20 is primarily produced by CD68þ /CD11cþ leukocytes in vivo
To determine the source of IL-20 in vivo, we double-stained
tissue with fluorescent antibodies against IL-20 (Cy3-labeled)
and CD68 (FITC-labeled) (Figure 4a–c). Based on our findings
that monocytes produce IL-20 in vitro, we chose CD68
because it identifies myeloid-derived leukocytes, including
monocytes/macrophages and some DCs (Pulford et al., 1990;
Nakamura et al., 1998). In NL skin, we found very little IL-20
or CD68 staining (Figure 4a). In contrast, we found intensely
positive staining for IL-20 and CD68 in LS skin (Figure 4b and
c). Although we noticed some diffuse staining in keratino-
cytes, IL-20-Cy3 appeared most strongly in mononuclear
cells in the papillary dermis near the dermo-epidermal
junction, as well as in sporadic mononuclear cells in the
epidermis. The staining pattern for CD68-FITC appeared very
similar, and when both fluorochromes were co-visualized,
there was a high degree of overlap, indicating that IL-20
protein was present in many CD68þ leukocytes in psoriatic
lesions. To confirm these findings, we also stained sections
with CD11c and found that IL-20þ cells partially overlapped
with cells expressing this marker (Figure 4d). CD11c
identifies myeloid-derived cells, including monocytes,
macrophages, myeloid DCs, and a recently identified subset
of inflammatory DCs that produce TNF-a and inducible nitric
oxide synthase (iNOS) (TNF- and iNOS-producing DCs)
(Lowes et al., 2005). Of note, we found that CD11cþ cells
were localized in the same region of psoriatic skin as CD68þ
cells (Figure 4d and Figure S1b).
As the most intense staining for CD68 and IL-20
demonstrated marked overlap, we attempted to identify
potential myeloid sources of IL-20 by characterizing
CD68þ cells in psoriasis. Firstly, by using flow cytometry,
we confirmed that CD68 identified myeloid cell populations
(CD11cþ ), including monocytes, in vitro-derived macro-
phages, and in vitro-generated mature DCs (Figure S1a).
Secondly, additional double staining of LS skin demonstrated
that CD68 partially overlapped with inflammatory DC
markers (CD11cþ , HLA-DRþ , DC-SIGNþ ), but not markers
of mature DCs (CD1b/cþ or CD83þ ) (Figure S1b–f). Little
overlap was seen with the classic monocyte/macrophage
marker CD14, which was minimally expressed in psoriatic
skin (Figure S1g). These findings suggest that the markers of
CD68þ leukocytes in psoriasis may be consistent with
immature DCs and, furthermore, with inflammatory TNF-
and iNOS-producing DCs. Thus, these cell types may be
important, but not exclusive, sources of IL-20 in vivo.
IL-20 expression is modulated by alefacept and correlates with
disease activity
To relate IL-20 to disease activity, we examined patients
treated with alefacept, a biological agent that preferentially
reduces T cells in psoriatic plaques (Chamian et al., 2005).
Based on histology, including epidermal hyperplasia and
keratin 16 (K16) immunostaining, patients were categorized
as responders (n¼ 12) or nonresponders (n¼8) after 13
weeks of treatment. In general, responders demonstrated
decreased T cells in LS skin at the end of treatment, as well
as normalization of epidermal thickness and K16 staining. In
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Figure 4. Immunofluorescent staining of IL-20, CD68, and CD11c in
psoriatic skin. (a–c) Two-color immunofluorescence for IL-20 (red,
Cy3-labeled) and CD68 (green, FITC-labeled) in (a) NL and (b and c) LS
psoriatic skin. The boxed region in (b) is enlarged in (c). (d) Two-color staining
for IL-20 (red, Alexa 568-labeled) and CD11c (green, Alexa 488-labeled) of
LS skin is also presented. In all panels, double positive cells appear yellow.
(e) As a control, LS skin was stained with IL-20 antibody, but no Cy3-
conjugated secondary antibody. (f) Isotype control (IgG-FITC) staining of LS
skin. Original magnification: (a, b, e, and f)  20; (c and d) 40.
Bar¼100 mm.
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11/12 responders, IL-20 mRNA decreased by the end of
therapy (Figure 5a), with mean expression being 571.9 before
treatment and 102.8 after treatment (Po0.004). This repre-
sented a decrease of 82% and an effective normalization of
IL-20 mRNA to NL quantities. In contrast, nonresponders
demonstrated sustained T-cell numbers, thickened epidermis,
and persistence of K16 staining in LS skin. In nonresponders,
IL-20 mRNA remained unchanged (Figure 5b). Whereas
mean expression in LS skin was 441.2 before treatment, it
was 557.2 after treatment (P¼0.66).
To verify our results, we performed immunostaining for
IL-20 protein. Before treatment, IL-20 staining in LS skin of
both responders and nonresponders was similar and loca-
lized mostly to mononuclear leukocytes in the papillary
dermis and lower-to-mid epidermis (e.g. as in Figure 2). At
the end of treatment, staining for IL-20 was virtually
nonexistent in responders, but persistent in nonresponders
(Figure 5c and d).
To correlate changes in IL-20 gene expression with clinical
response, we used a previously described multivariate
u-score method that considers multiple parameters to
measure disease improvement in both responders and
nonresponders (Wittkowski et al., 2004; Gottlieb et al.,
2005). For our parameters, we used epidermal thickness, K16
mRNA expression, and K16 staining at week 13 of alefacept
treatment and calculated a response score using these
criteria. We then correlated response score to changes in
IL-20 expression. IL-20 mRNA expression was highly
correlated (r¼ 0.70) with objective parameters of disease
activity (i.e. response score) (Figure 5e), suggesting that IL-20
expression closely paralleled clinical response to alefacept.
Using u-statistics for multivariate data, we took into account
changes in the expression of other genes and found that IL-20
expression had the highest correlation to response score
when IL-8 and monokine induced by IFN-g (MIG) expression
was also considered (r¼ 0.79) (Figure 5f). This suggested that
IL-20 expression was additionally correlated with known
disease-related pathways.
IL-20 induces expression of IFN-regulated and disease-related
genes in keratinocytes
Lastly, we examined the effects of IL-20 on keratinocytes.
Previously, it was reported that keratinocytes possess IL-20
receptors and therefore are a target for IL-20 (Blumberg et al.,
2001; Romer et al., 2003). We verified that one of the receptor
subunits, IL-20Ra, was present on keratinocytes in vivo (Figure
2e and f). In addition, we found that keratinocytes in culture
(HaCaT cells) expressed substantial IL-20Ra, IL-20Rb, and
IL-22R mRNA (data not shown). Therefore, we postulated that
IL-20 might induce important responses in keratinocytes.
To investigate this, we used Affymetrix U95 microarrays to
analyze HaCaT cells stimulated with recombinant IL-20. We
found that IL-20 induced genes involved in regulation of
proliferation, apoptosis, or epidermal differentiation. These
include PI3/SKALP, BIRC3, TNFAIP3, PTHLH, SPRR1A, RAI3,
NINJ1, TGM1, and SPRR1B (Figure 6a). In addition, IL-20
upregulated various genes involved in immune response
(SERPINB4, SERPINB3, IL-1R2, RELB, and IKBKE), chemo-
taxis (CXCL1, IL-8, CXCL6, and CCL20), angiogenesis
(TNFAIP2), and collagen metabolism (MMP-7 and MMP-
13). Based on previous microarray studies of psoriasis
(Bowcock et al., 2001; Oestreicher et al., 2001; Zhou
et al., 2003), many of these are considered to be disease-
associated genes. Figure 6a lists genes that were most highly
upregulated by IL-20.
IL-20 also stimulated the expression of many IFN-
regulated genes. Among these were signal transducer and
activator of transcription 1 (STAT1), IFN-g-inducible protein
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Figure 5. IL-20 mRNA is modulated by alefacept treatment and correlates
with disease activity. RT-PCR quantification of IL-20 mRNA (normalized to
hARP) in (a) alefacept responders and (b) nonresponders. A black line
connects samples taken from an individual psoriasis patient’s LS skin before
and after treatment with alefacept. ~ Indicates the mean for each type of
specimen. Asterisk (*) indicates statistical significance (Po0.05) between
baseline and post-treatment results. IL-20 staining of skin at the end of
treatment from (c) a responder and (d) a nonresponder (original magnification
20). Bar¼ 100mm. Correlation plots with linear regression (line of best fit)
were used to compare response score (disease activity) with change in gene
expression for (e) IL-20 or (f) a set of disease-related genes including IL-20.
Black squares represent an individual psoriasis patient’s response score
plotted against change in mRNA (pre- vs post-treatment). Response score was
determined by change in epidermal thickness, K16 mRNA, and K16 staining
with treatment. Higher response score values indicate improvement in these
disease parameters with treatment.
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16 (IFI-16), and IFN regulatory factor 7 (IRF-7). IL-20 has not
been previously reported to possess IFN-like properties. As
such, we treated a separate group of HaCaT cells with IFN-g
alone and examined their expression profile. Comparing this
to the group of genes upregulated by IL-20, we found at least
38 overlapping genes. Thus, IL-20 appeared to induce a
subset of genes that also respond to IFN-g. Besides those
already mentioned, these include genes involved in tran-
scription (STAT3, SP110, NMI), protein synthesis (WARS),
Th1 polarization (IL-15Ra), antigen presentation (TAP1,
PSMB9, PSBM10, and PSME2), leukocyte trafficking (CCL2/
MCP-1, CD47, CCL17/TARC, CX3CL1, and CXCL1/GRO-a),
innate immunity (OAS1, BF, and MYD88), growth (ECGF1),
and apoptosis (CASP1, CASP10, and PLAT). Many of these
genes, including STAT1, CCL2, CD47, PSME2, STAT3, and
IRF-7, have been previously described as disease-related,
based on microarrays of psoriatic lesions. Figure 6b lists
overlapping genes upregulated by IL-20 and IFN-g.
Genes 
upregulated
by IL-20 
(31 genes)
Genes 
upregulated
by IFN-
(131)
Both
(38)
3.1 PLAT Tissue plasminogen activator 
2.6 SERPINB1 Serine proteinase inhibitor, clade B (ovalbumin), member 1 
2.4 CCL2* Monocyte chemotactic protein-1 
2.3 CCL17 TARC 
2.3 STOM Stomatin
1.9 CD47* CD47 antigen 
1.7 TRB2 Tribbles homolog 2 
1.7 BF B-factor, properdin 
1.7 CXCL3 GRO-
1.6 UBD Ubiquitin D 
1.6 STAT3* Signal transducer and activator of transcription 3 
1.6 WARS Tryptophanyl-tRNA synthetase 
1.6 SECTM1 Secreted and transmembrane 1 
1.5 CX3CL1 Fractalkine 
1.5 IL15RA Interleukin-15 receptor-α
1.5 PML  Promyelocytic leukemia
1.5 UBE2L6 Ubiquitin-conjugating enzyme E2L 6 
1.4 P2RY6 Pyrimidinergic receptor P2Y, G-protein coupled, 6 
1.4 TAP1 Transporter associated with antigen processing 1 
1.4 ECGF1 Endothelial cell growth factor 1 
1.4 STAT1* Signal transducer and activator of transcription 1 
1.4 XDH Xanthine dehydrogenase 
1.4 SP110 IFN-induced human nuclear phosphoprotein 
1.4 PSMB9 Proteasome subunit  9 
1.4 IFI16 Interferon- -inducible protein 16
1.4 OAS1 Homo sapiens 2′-5′ oligoadenylate synthetase
1.4 CASP10 Caspase 10 
1.3 INPP1 Inositol polyphosphate-1-phosphatase 
1.3 CASP1 Caspase 1 
1.3 BAZ1A Bromodomain adjacent to zinc finger domain 1A
1.3 PSME2 Proteasome activator subunit 2 (PA28 ) 
1.3 MYD88 Myeloid differentiation primary response gene 88
1.3 SP100 Nuclear antigen Sp100 
1.3 TMSB10 Thymosin  10
1.2 PSMB10 Proteasome subunit 10 
1.2 SSA1 Sjogren syndrome antigen A1
1.2 NMI N-myc (and STAT) interactor
1.2 IRF7* Interferon regulatory factor 7 
Fold Symbol Gene product 
Fold Symbol Gene product 
4.5 SERPINB4* Serine proteinase inhibitor, clade B (ovalbumin), member 4 
4.0 CXCL1* GRO- 
3.1 PI3* SKALP/elafin
3.1 BIRC3  Baculoviral IAP repeat-containing 3 
2.5 IL-8* Interleukin-8 
2.5 CXCL6 Granulocyte chemotactic protein 2 
2.4 CCL20* MIP-3
2.4 SERPINB3* Serine proteinase inhibitor, clade B (ovalbumin), member 3 
2.2 TNFAIP3 TNF- -induced protein 3 
2.2 MMP7 Matrilysin
2.1 PTHLH  Parathyroid hormone-like hormone 
1.9 SPRR1A  Small proline-rich protein 1A
1.8 TNFAIP2 TNF- -induced protein 2 
1.8 MMP13 Collagenase 3 
1.7 IL-1R2 Interleukin-1 receptor, type II
1.6 HRASLS3  HRAS-like suppressor 3 
1.6 ABTB2  Ankyrin repeat and BTB (POZ) domain containing 2 
1.6 NINJ1 Ninjurin 1 
1.5 TGM1* Transglutaminase 
1.5 RELB V-rel reticuloendotheliosis viral oncogene homolog B 
1.5 KIAA0133  KIAA0133 gene product 
1.4 AMD1* Adenosylmethionine decarboxylase 1 
1.4 FHL2 Four and a half LIM domains 2 
1.4 PLAUR Six transmembrane epithelial antigen of the prostate 1 
1.4 STEAP1 BAC clone CTB-41D11 from 7 
1.3 RAI3 Retinoic acid induced 3 
1.3 DTR  Heparin-binding EGF-like growth factor
1.3 IKBKE Inhibitor of NF-B kinase epsilon subunit   
1.3 uPA Urokinase-type plasminogen activator 
1.3 CD83* CD83 antigen 
1.3 SPRR1B* Small proline-rich protein 1B (cornifin)
a b
Figure 6. IL-20-induced upregulation of IFN-c-regulated and psoriasis disease-associated genes in keratinocytes. (a) Keratinocytes (HaCaT cells) were treated
with recombinant IL-20 and their gene expression profile analyzed using microarrays. Genes that were upregulated at least 1.2-fold are listed. (b) For
comparison, a group of HaCaT cells was treated separately with IFN-g and analyzed with microarray screening. Overlapping genes that were upregulated by
IFN-g and IL-20 (at least 1.2-fold) are listed. Asterisk (*) indicates a known psoriasis disease-associated gene, based on three previous microarray reports of
psoriasis.
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DISCUSSION
To explain cytokine interactions in the pathogenesis of
psoriasis, we have previously proposed a working hypothesis
called the ‘‘Type 1 pathway’’ (Lew et al., 2004a, b; Lowes
et al., 2004; Wang et al., 2004; Bowcock and Krueger, 2005).
In this model, upstream cytokines such as IL-12 and IL-23
stimulate T cells to produce IFN-g and TNF-a, resulting in
activation of relevant transcription factors (STAT1 and NF-kB,
respectively). This induces inflammatory mediators such as
iNOS, IL-8, and MIG, which may activate keratinocytes and
endothelial cells, ultimately leading to the psoriatic pheno-
type. IL-20 is consistently elevated in psoriatic skin, indicat-
ing that it is highly correlated with disease. However, IL-20
was not regulated by IFN-g, but instead by cell adhesion and
TNF-a. Thus, the production of this cytokine potentially
introduces a new pathogenic inflammatory pathway that is
independent of the Type 1 pathway. Alternatively, as TNF-a
induces IL-20 and is produced by Type 1 T cells, the
induction of IL-20 may represent a branch point in the Type 1
pathway. With regard to its effector functions, IL-20 induces a
pattern of genes that define psoriasis and that are usually
considered to be IFN-g-regulated. This broadens the defini-
tion of cytokines that are able to induce ‘‘IFN-g-responsive
genes’’ and other disease-related genes.
Our observations of IL-20 receptors in psoriasis contrast
with previous reports (Blumberg et al., 2001; Romer et al.,
2003; Wei et al., 2005). We found gene expression for
IL-20Ra/IL-20Rb and protein expression for IL-20Ra to be
decreased in LS skin. Based on immunostaining, IL-20Ra
appeared to be diminished in the middle and lower
epidermis. Given the limitations of cytokine diffusion, IL-20
derived from leukocytes near the dermo-epidermal junction
may act on more proximal keratinocytes and induce
transcriptional downregulation or internalization of the
receptors. We also observed that gene expression of the
receptor subunits in normal skin was not significantly
different from LS or NL psoriatic skin. Previously, it was
suggested that upregulation of IL-20 receptors implied a role
for IL-20 in psoriasis (Blumberg et al., 2001). However, our
finding suggests that the effects of IL-20 are mediated by
differential expression of the cytokine itself, rather than by
significant changes in its receptors.
Although diffuse IL-20þ staining was sometimes observed
in keratinocytes, we identified a major in vivo source of IL-20
to be infiltrating CD68þ and CD11cþ leukocytes (Figure 4).
This result extends previously published studies implicating a
keratinocyte origin (Romer et al., 2003; Wei et al., 2005).
CD68 identifies myelomonocytic cells (Nakamura et al.,
1998) that localize to the papillary dermis of psoriasis lesions
(Gillitzer et al., 1993). CD68 also overlaps with a subset of
cells expressing CD11c (Figure S1b), a marker of monocytes/
macrophages and certain DCs that produce TNF-a and iNOS
in psoriasis (Lowes et al., 2005). Blood-derived myeloid leuko-
cytes clearly have the capacity to synthesize IL-20 (Figure 3a).
Together with in vivo data indicating that CD68þ cells do not
overlap with monocytes, or mature DCs (Figure S1), we
suggest that myeloid-derived leukocytes, in particular imma-
ture DCs and/or inflammatory TNF- and iNOS-producing DCs,
may be important, but not exclusive, sources of IL-20 in
psoriasis.
Production of IL-20 mRNA in myeloid-derived cells
(monocytes) after plastic adherence suggested that ‘‘outside-
in’’ cellular activation may induce IL-20 expression. Indeed,
we found that IL-20 mRNA was increased in cells after b2
integrin ligation (Figure 3c). However, as this induction was
modest, the role of cytokines may potentially be more impor-
tant for IL-20 induction. In particular, TNF-a appeared to
increase IL-20 production (Figure 3d), demonstrating that
multiple mechanisms may activate IL-20 synthesis. Given that
myeloid-derived leukocytes in psoriasis may produce
IL-20 and TNF-a (Wang et al., 2004), it is possible that
TNF-a acts in an autocrine fashion to upregulate IL-20. TNF-a
derived from T cells, keratinocytes, and other cells may
contribute to this process. Interestingly, we found that IFN-g
did not promote IL-20 production, which supports our
suggestion that IL-20 is not directly regulated by IFN
and that it may be induced outside the Type 1 pathway. The
stimulation of IL-20 by TNF-a does not contradict this, as the
induction of certain inflammatory molecules by TNF-a is
independent of Type 1 (STAT1- or NF-kB-mediated) pathways.
Thus, the stimulation of IL-20 by TNF-a may alternatively
indicate a branch point in the Type 1 signaling cascade.
To better relate IL-20 to disease activity, we studied
patients treated with alefacept, an LFA-3Ig fusion protein that
targets CD2 on T cells. Using response score as an objective
measure of outcome, we found that IL-20 mRNA expression
closely paralleled clinical disease activity (Figure 5e).
Response score combined epidermal thickness, K16 mRNA,
and K16 staining (Wittkowski et al., 2004; Chamian et al.,
2005; Gottlieb et al., 2005). Moreover, when changes in the
disease-associated genes IL-8 and MIG were included in the
analysis, IL-20 became even more highly correlated with
response score (Figure 5f). As a single gene product, IL-20
mRNA exhibited an extremely high correlation with disease
activity, and overall, this is similar to disease relationships
seen with products like iNOS and IL-12p40 (IL-23p40)
(Wittkowski et al., 2004; Gottlieb et al., 2005). Considering
that alefacept preferentially targets T cells, this may also
argue that T cells are involved in the proximal regulation of
IL-20, possibly via TNF-a elaboration.
To investigate downstream effects of IL-20, we used
microarrays to screen keratinocytes stimulated with IL-20.
We found three groups of induced genes: known psoriasis
disease-associated genes, certain IFN-inducible genes, and a
group of genes with potentially important disease regulatory
activity. Firstly, by comparing IL-20-induced genes with three
published microarray studies of psoriasis (Bowcock et al.,
2001; Oestreicher et al., 2001; Zhou et al., 2003), we found
that IL-20 promoted the expression of previously described
disease-associated genes. These include the neutrophil chemo-
attractants CXCL1 (GRO-a) and IL-8, as well as the DC/T-cell
chemoattractant CCL20 (MIP-3a). SERPIN B4 and SERPIN B3
are two highly upregulated genes in psoriasis (Zhou et al.,
2003), and these were two of the top genes induced by IL-20.
Interestingly, these two genes were not upregulated in IFN-
stimulated keratinocytes, which suggests that IL-20 can exert
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some of its effects through IFN-independent pathways. IL-20
also influenced disease-related genes associated with epider-
mal differentiation (TGM1, SPRR1B, and SKALP).
Secondly, by comparing IFN-g- and IL-20-treated kerati-
nocytes, we found that IL-20 upregulated at least 38
IFN-inducible genes. These include several prototypical
IFN-inducible transcriptional modulators (STAT1, IFI-16, and
IRF-7), as well as other disease-defining genes (CCL2/MCP-1,
CD47, and PSME2). Given the time course of our experi-
ments (exposure to IL-20 for 4 hours), it is likely that IL-20
achieves this by directly activating IFN-response elements.
Considering that IL-20 may be derived mostly from myelo-
monocytic cells, this potentially suggests a greater role for
innate immune mechanisms in augmenting psoriatic inflam-
mation through IFN-like effects.
Thirdly, we found that IL-20 induced additional genes that
have not been previously implicated in psoriasis, but
potentially have important regulatory activity. For instance,
IL-20 may influence keratinocyte hyperproliferation by
inducing genes that are cell growth promoting (RAI3) or
antiapoptotic (BIRC3 and TNFAIP3). IL-20 may play a role
in neovascularization by upregulating the angiogenic
factor TNFAIP2 and by inducing metalloproteinase synthesis
(MMP-7 and MMP-13). In addition, IL-20 may influence
inflammation by upregulating CXCL6 (GCP-2), a neutrophil
chemotactic factor.
Overall, our results potentially define an important source
and role for IL-20. Currently, a working hypothesis is
that IFN-g and TNF-a are the major cytokines driving
Type 1 inflammation in psoriasis. Our studies demonstrate
that IL-20 specifically induces IFN-like effects in keratino-
cytes. Moreover, it is possible that the effects of IL-20
may overlap with TNF-a. Our microarray studies demonstrate
that IL-20 can activate the TNF-inducible transcription
factor RELB, which is a part of the NF-kB2 complex.
Therefore, we believe that IL-20 is an effector cytokine
with important functions in psoriasis. Although IL-20 may
not directly induce inflammation (i.e. leukocyte activation),
the net effect of this cytokine may be inflammatory through
its actions on keratinocytes. Furthermore, the inhibition
of IL-20 or its receptors may represent potential therapy
for patients. Preliminary studies indicate that anti-IL-20
antibodies reverse phenotype in a psoriatic skin-severe
combined immunodeficient mouse transplant model
(Kjeldsen et al., 2005). As such, it will be interesting to
further define the role of IL-20 in psoriasis by using specific
antagonists.
MATERIALS AND METHODS
Psoriasis subjects
In a Rockefeller University Hospital Institutional Review Board-
approved protocol, 34 adults with psoriasis (affecting 5–10% of body
surface area) provided written consent for LS and NL skin biopsies.
The study was conducted according to the Declaration of Helsinki
Principles. Before this, patients had no systemic and topical
treatment for 4 and 2 weeks, respectively. Additionally, 11 normal
volunteers had biopsies. Half of each biopsy was frozen in OCT
(Sakura Finetechnical, Tokyo, Japan) and stored at 801C for
immunohistochemistry, and the remaining section stored in liquid
nitrogen until analysis.
TaqMan RT-PCR quantitation of mRNA
RNA extraction and TaqMan RT-PCR assays were performed as
described previously (Chamian et al., 2005). To prevent false
negative results due to absent mRNA, we measured hARP and
found appropriate expression in all cells/tissue samples (data not
shown). Owing to inadequate mRNA, data were obtained in only 5/8
alefacept nonresponders. Sequences of primers and probes can be
found as Supplementary material.
Statistical analysis
Paired Student’s t-test was used to compare LS, NL, and normal skin
gene expression levels. Significance was accepted as Po0.05.
Immunohistochemistry
Tissue sections were stained with monoclonal mouse anti-human
IL-20 antibody (R&D Systems, Minneapolis, MN) followed by
biotin-labeled horse anti-mouse antibody (Vector Laboratories,
Burlingame, CA), or polyclonal goat anti-human IL-20Ra antibody
(R&D Systems) followed by biotin-labeled rabbit anti-goat
antibody (Vector Laboratories). Secondary antibodies were
amplified with avidin–biotin complex (Vector Laboratories) and
developed with 3-amino-9-ethylcarbazole chromogen (Sigma-Al-
drich, St Louis, MO).
In vitro cell studies
PBMCs were isolated from buffy coats using Ficoll–Paque
PLUS (Amersham Biosciences, Piscataway, NJ). Lymphocytes
were isolated from nonadherent PBMCs following incubation on
polystyrene culture dishes for 2 hours at 371C. T cells were isolated
from whole blood using a T-Cell Negative Isolation Kit (Dynal
Biotech, Brown Deer, WI) and activated for 24 hours using the
Dynabeads CD3/CD28 T-Cell Expander Kit (Dynal Biotech). HaCaT
cells were grown in DMEM (Gibco-BRL Life Technologies, Gaithers-
burg, MD) with 10% fetal bovine serum (HyClone Laboratories Inc.,
Logan, UT) and activated with 10mg/ml recombinant IFN-g (R&D
Systems) for 24 hours at 371C. Monocytes were isolated from buffy
coats using a Monocyte Negative Isolation Kit (Dynal Biotech). For
adherence, monocytes were incubated in RPMI-1640 (Gibco-BRL Life
Technologies) on 100 mm 20 mm polystyrene culture plates (BD
Falcon, San Jose, CA) for 2 hours at 371C. For integrin experiments,
monocytes (0.5–1 million cells/ml) were incubated in 15 ml conical
tubes (BD Falcon) in RPMI-1640 with 10% normal human serum
(Labquip Ltd, Niagara Falls, NY) for 2 hours at 371C with b1 integrin
antibodies (Chemicon, Temecula, CA), b2 integrin antibodies
(Chemicon/Cymbus Biotech and Calbiochem, San Diego, CA), or
mouse IgG1 control (Chemicon). For cytokine activation experiments,
monocytes were isolated as described previously (Dhodapkar et al.,
2005) and incubated for 6, 24, or 48 hours at 371C with 10mg/ml of
IFN-g (R&D Systems) or 10 ng/ml of TNF-a (R&D Systems). For DC
generation, monocytes (purity 495%) were cultured to mature DCs
as described previously (Dhodapkar et al., 2002).
Immunofluorescence
After acetone fixation and treatment with 10% normal horse serum
(Vector Laboratories), tissue sections were incubated with IL-20
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antibody (R&D Systems) (1:10), then with Cy3-labeled secondary
antibody (Jackson Immunoresearch, West Grove, PA) (1:100),
followed by CD68-FITC antibody (Dako, Carpinteria, CA) (1:200).
Controls were mouse IgG1-FITC (BD Biosciences), or IL-20 antibody
without a secondary antibody. For CD11c staining, sections were
fixed in acetone and treated with 10% normal goat serum (Vector
Laboratories). Sections were incubated overnight with IL-20 antibody
(R&D Systems) (1:10), then IgG1 goat anti-mouse secondary antibody
conjugated to Alexa 568 (Molecular Probes, Eugene, OR) (1:250) for
30 minutes, followed by CD11c (BD Pharmingen) custom conjugated
to Alexa 488 (MSKCC mAb Core Facility, New York, NY) (1:10) for
2 hours. Images were acquired as described previously (Chamian
et al., 2005; Gottlieb et al., 2005).
Alefacept studies
Twenty-two patients with moderate to severe psoriasis were treated
with alefacept (7.5 mg/kg/week for 12 weeks) and determined to be
‘‘responders’’ or ‘‘nonresponders’’ as described previously (Chamian
et al., 2005). Gene expression analysis and statistical correlation
with disease activity (u-statistics, response score) were performed as
described previously (Wittkowski et al., 2004; Chamian et al., 2005;
Gottlieb et al., 2005).
Gene arrays
Confluent HaCaT cells grown in DMEM with 10% fetal bovine
serum were changed to serum-free media overnight. Cells were
treated in triplicate for 4 hours with 10 nM human IL-20 (Biosource
International, Camarillo, CA), 100 ng/ml IFN-g (R&D Systems), or no
cytokine. RNA was obtained as above and hydridized to Affymetrix
(Santa Clara, CA) HuGeneU95 Av2 microarrays, according to the
manufacturer’s protocol. Raw fluorescent intensity values were ana-
lyzed using GeneChip Operating software version 1.2 (Affymetrix)
and GeneSpringTM. Data for triplicates were averaged.
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